PetMed Express Inc. (PETS) carries a Roarable Rating of E (Strong Sell) with 19/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, PetMed Express Inc. (NASDAQ: PETS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $1.18 (-0.84% 1D, market cap $25.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 146 tracked Consumer Staples issuers, PETS ranks #145 in composite RQD confidence.
Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), PETS carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -35.0%. By comparison, YI (111 Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -20.5%, cap $26.2M) and RDGT (Ridgetech Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC —, cap $3.0M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).
Per PETS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001040130), PetMed Express Inc. generated $179.0M in revenue (-21.1% YoY), -$57.3M in net income, and -$33.0M in free cash flow against $88.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Staples with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 33.1 (NEUTRAL RANGE)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 28.1% Gross Margin
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While PETS currently carries a cautious 19/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Consumer Staples with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.47) and Max Pain ($1.24) forces dealer call-delta covering toward $4.30.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
PetMed Express Inc. (PETS) slipped -0.84% to $1.18, trading at 2% of its 52-week range ($1.15 – $4.1). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
DELRAY BEACH, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS) today announced it will report financial results for the second quarter fiscal year
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -21.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on PETS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for PETS. Explore sector supply chains on /butterfly.
Across 146 tracked Consumer Staples securities in the Roarable RQD universe, PetMed Express Inc. (PETS) ranks #145 by composite RQD confidence (19/100, grade E) and #117 by equity capitalization ($25.6M). Within this direct 5-issuer industry benchmark cohort, GRDN leads on earnings valuation at 52.1x trailing P/E, while GRDN leads on capital efficiency and profitability with 37.7% ROIC and 20.2% gross margin. GRDN currently holds the highest overall quantitative score in the immediate peer group at 71/100 (B-) compared with PETS at 19/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| PETS
ACTIVE
PetMed Express Inc. | E | 19/100 | — | 28.1% | -35.0% | -0.84% | $25.6M | Benchmark Subject |
| YI 111 Inc. | D- | 37/100 | — | 5.8% | -20.5% | +0.34% | $26.2M | /yi-vs-pets → |
| RDGT Ridgetech Inc. | D- | 37/100 | — | 3.6% | — | -2.45% | $3.0M | /rdgt-vs-pets → |
| GRDN Guardian Pharmacy Services Inc. (Class A) | B- | 71/100 | 52.1x | 20.2% | 37.7% | +0.30% | $2.56B | /grdn-vs-pets → |
| CVS CVS Health Corporation | C- | 61/100 | 65.3x | 45.0% | 2.6% | +0.42% | $115.53B | /cvs-vs-pets → |
In its most recent audited fiscal period (FY2025, filed 2026-03-31), PetMed Express Inc. (PETS) reported GAAP revenue of $179.0M (-21.1% vs. FY2024 revenue of $227.0M , and -34.7% cumulative change since FY2023) , GAAP net income of -$57.3M, operating cash flow of -$28.4M, and free cash flow of -$33.0M (-8256.7% YoY). On the balance sheet, PETS closed FY2025 with $88.0M in total assets against $0 in total debt (Altman Z-Score: 0.24, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2026-03-31 | $179.0M | -$57.3M | -$28.4M | -$33.0M | $88.0M | — |
| FY2024 (FY) | 2025-03-31 | $227.0M | -$6.3M | $4.7M | -$395.0K | $144.8M | — |
| FY2023 (FY) | 2024-03-31 | $274.1M | -$7.5M | $4.3M | $4.3M | — | — |
As of 2026-11-02, PetMed Express Inc. (NASDAQ: PETS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 19/100 at a spot price of $1.18 (-0.84% 1D, market cap $25.6M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 3/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 146 tracked Consumer Staples issuers, PETS ranks #145 in composite RQD confidence.
Within the Consumer Staples sector (Retail-Drug Stores and Proprietary Stores), PETS carries a Roarable E (19/100 RQD), trailing P/E of N/A, gross margin of 28.1%, and ROIC of -35.0%. By comparison, YI (111 Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -20.5%, cap $26.2M) and RDGT (Ridgetech Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC —, cap $3.0M). Among the 5-stock peer group, GRDN leads on earnings multiple (52.1x) while GRDN leads on capital efficiency (37.7% ROIC).
Per PETS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001040130), PetMed Express Inc. generated $179.0M in revenue (-21.1% YoY), -$57.3M in net income, and -$33.0M in free cash flow against $88.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Staples with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
PETS last traded at $1.18 (-0.84% on volume of 12,520 shares), positioning the stock -19.73% below its 50-day simple moving average ($1.47) and -43.81% below its 200-day simple moving average ($2.10). Across its 52-week range of $1.15 to $4.10, PETS sits at the 1.0% percentile with a 14-day RSI of 33.1 (NEUTRAL RANGE) and an implied next-earnings move of ±7.8% ($1.09 to $1.27).
Why PETS Stock slipped -0.84% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).